CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis (CAMB)

This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or intolerant to standard non intravenous therapies.


Condition Intervention Phase
Candidiasis, Chronic Mucocutaneous Drug: Amphotericin B Phase 2


Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies

Antifungal name: 

Date of article/Start date of trial: 

Thursday, December 15, 2016

Trial phase: 

Phase 2 ID: 


Trial status: 

New antifungal drugs